Finding 980262 (2022-005)

Material Weakness Repeat Finding
Requirement
L
Questioned Costs
-
Year
2022
Accepted
2024-06-28

AI Summary

  • Core Issue: The Organization failed to submit timely and properly approved monthly reports to the DMVA, leading to potential inaccuracies and unsupported expenditures.
  • Impacted Requirements: Monthly progress reports and invoices must be submitted within specified timeframes as per grant agreements; lack of adherence risks reimbursement approval.
  • Recommended Follow-Up: Establish a formal review process for monthly reports, ensuring they are signed, dated, and submitted on time, along with proper documentation for budget modifications.

Finding Text

#2022-005 – Material Weakness – Reporting Opioid STR Grant ALN 93.788 Block Grants for Prevention and Treatment of Substance Abuse 93.959 Criteria The Organization’s agreements with the Department of Military and Veterans Affairs (DMVA) requires the Organization to submit monthly progress reports no later than 13 business days after the end of each month. Per the agreements with the Drug and Alcohol Programs, "Unless otherwise specified elsewhere in this Grant Agreement, the following shall apply. Grantee shall submit monthly invoices within 30 days from the last day of the month within which the work is performed. The final invoice shall be submitted within 45 days of the Grant Agreement’s termination date. The Department will neither honor nor be liable for invoices not submitted in compliance with the time requirements in this paragraph unless the Department agrees to an extension of these requirements in writing. The Grantee shall be reimbursed only for services acceptable to the Department." Condition During the audit we were not able to obtain the monthly reports filed with the DMVA properly approved by management and there was no date to indicate that the reports were filed within the appropriate period required by the grant agreements. During our audit, we noted that the Organization reallocated expenses across budget line items without a formal budget modification or tracking of the reallocation. The reallocations were not properly documented and resulted in unsupported expenditures charged to the grant programs. Cause The Organization does not have proper internal controls which include the review and approval of monthly reports filed with granting agencies for accuracy and completeness. These policies and procedures should also ensure that all reports are filed within the timeframe in accordance with the grant contract. The Organization also lacks a formal process for budget modifications and tracking of related expense adjustments. Effect The potential effect of not having proper review and approval of monthly reports is the potential for errors in the reports that would be caught by an independent review and improper reporting to the granting agencies. Reports not submitted within the required timeframe may not be approved for reimbursement. Questioned Costs None Perspective Information We reviewed a sample of reports filed with the Drug and Alcohol Program. The finding represents errors noted in all reports reviewed. Identification as a repeat finding A similar issue was noted in prior year finding #2021-005. Recommendation We recommend that the Organization implement policies and procedures to include a second independent review of the monthly reports filed with the granting agencies for accuracy and completeness. Monthly reports should be properly signed and dated to indicate this review and timely filing of the reports. Additionally, the reports should be filed on the correct basis of accounting and only include expenses of the period for which they are filed.

Categories

Allowable Costs / Cost Principles Cash Management Material Weakness Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 403816 2022-001
    Material Weakness Repeat
  • 403817 2022-002
    Material Weakness Repeat
  • 403818 2022-003
    Material Weakness Repeat
  • 403819 2022-004
    Material Weakness Repeat
  • 403820 2022-005
    Material Weakness Repeat
  • 403821 2022-006
    Material Weakness Repeat
  • 403822 2022-007
    Significant Deficiency Repeat
  • 403823 2022-001
    Material Weakness Repeat
  • 403824 2022-002
    Material Weakness Repeat
  • 403825 2022-003
    Material Weakness Repeat
  • 403826 2022-004
    Material Weakness Repeat
  • 403827 2022-005
    Material Weakness Repeat
  • 403828 2022-006
    Material Weakness Repeat
  • 403829 2022-007
    Significant Deficiency Repeat
  • 980258 2022-001
    Material Weakness Repeat
  • 980259 2022-002
    Material Weakness Repeat
  • 980260 2022-003
    Material Weakness Repeat
  • 980261 2022-004
    Material Weakness Repeat
  • 980263 2022-006
    Material Weakness Repeat
  • 980264 2022-007
    Significant Deficiency Repeat
  • 980265 2022-001
    Material Weakness Repeat
  • 980266 2022-002
    Material Weakness Repeat
  • 980267 2022-003
    Material Weakness Repeat
  • 980268 2022-004
    Material Weakness Repeat
  • 980269 2022-005
    Material Weakness Repeat
  • 980270 2022-006
    Material Weakness Repeat
  • 980271 2022-007
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $1.16M
93.959 Block Grants for Prevention and Treatment of Substance Abuse $615,643